Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reuben Domike

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
International Journal of Pharmaceutics|February 17, 2010
Light induced fluorescence for predicting API content in tablets: sampling and errorReuben Domike, Samuel Ngai, Charles L Cooney
Orphanet Journal of Rare Diseases|November 8, 2024
Expediting treatments in the 21st century: orphan drugs and accelerated approvalsReuben Domike, G K Raju, Jamie Sullivan, et al.
JCO Clinical Cancer Informatics|August 28, 2020
Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung CancerGokaraju K Raju, Sean Khozin, Karthik Gurumurthi, et al.
Clinical Pharmacology and Therapeutics|April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: MelanomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Pharmacology and Therapeutics|July 30, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell CarcinomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
PDA Journal of Pharmaceutical Science and Technology|October 14, 2022
MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing FacilityAndrea L Koenigsberg, Veronica Fowler, Reuben Domike, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
International Journal of Pharmaceutics|February 17, 2010
Light induced fluorescence for predicting API content in tablets: sampling and errorReuben Domike, Samuel Ngai, Charles L Cooney
Orphanet Journal of Rare Diseases|November 8, 2024
Expediting treatments in the 21st century: orphan drugs and accelerated approvalsReuben Domike, G K Raju, Jamie Sullivan, et al.
JCO Clinical Cancer Informatics|August 28, 2020
Patient-Centered Approach to Benefit-Risk Characterization Using Number Needed to Benefit and Number Needed to Harm: Advanced Non-Small-Cell Lung CancerGokaraju K Raju, Sean Khozin, Karthik Gurumurthi, et al.
Clinical Pharmacology and Therapeutics|April 18, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: MelanomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Pharmacology and Therapeutics|July 30, 2019
Using a Benefit-Risk Analysis Approach to Capture Regulatory Decision Making: Renal Cell CarcinomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
Clinical Pharmacology and Therapeutics|September 14, 2017
A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple MyelomaG K Raju, Karthik Gurumurthi, Reuben Domike, et al.
PDA Journal of Pharmaceutical Science and Technology|October 14, 2022
MIT CAACB Risk Assessment Case Study: Assessing Virus Cross-Contamination Risk between Two Simultaneous Processes in an Open Biomanufacturing FacilityAndrea L Koenigsberg, Veronica Fowler, Reuben Domike, et al.
Pageof 1